Head to Head Contrast: ImmunoGen (IMGN) vs. Ohr Pharmaceuticals (OHRP)

ImmunoGen (NASDAQ: IMGN) and Ohr Pharmaceuticals (NASDAQ:OHRP) are both small-cap healthcare companies, but which is the better business? We will contrast the two companies based on the strength of their earnings, institutional ownership, profitability, dividends, analyst recommendations, risk and valuation.

Volatility & Risk

ImmunoGen has a beta of 2.2, indicating that its stock price is 120% more volatile than the S&P 500. Comparatively, Ohr Pharmaceuticals has a beta of 0.48, indicating that its stock price is 52% less volatile than the S&P 500.

Profitability

This table compares ImmunoGen and Ohr Pharmaceuticals’ net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
ImmunoGen -130.00% N/A -49.89%
Ohr Pharmaceuticals N/A -99.97% -81.40%

Analyst Ratings

This is a summary of recent ratings and target prices for ImmunoGen and Ohr Pharmaceuticals, as provided by MarketBeat.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
ImmunoGen 1 2 5 0 2.50
Ohr Pharmaceuticals 0 1 1 0 2.50

ImmunoGen currently has a consensus price target of $8.05, indicating a potential upside of 20.15%. Ohr Pharmaceuticals has a consensus price target of $8.50, indicating a potential upside of 2,079.49%. Given Ohr Pharmaceuticals’ higher possible upside, analysts clearly believe Ohr Pharmaceuticals is more favorable than ImmunoGen.

Earnings & Valuation

This table compares ImmunoGen and Ohr Pharmaceuticals’ top-line revenue, earnings per share and valuation.

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
ImmunoGen $60.00 million 14.77 -$143.65 million ($1.30) -5.15
Ohr Pharmaceuticals N/A N/A -$23.81 million ($0.59) -0.66

Ohr Pharmaceuticals has lower revenue, but higher earnings than ImmunoGen. ImmunoGen is trading at a lower price-to-earnings ratio than Ohr Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Insider & Institutional Ownership

68.0% of ImmunoGen shares are owned by institutional investors. Comparatively, 8.3% of Ohr Pharmaceuticals shares are owned by institutional investors. 6.5% of ImmunoGen shares are owned by insiders. Comparatively, 17.4% of Ohr Pharmaceuticals shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

About ImmunoGen

ImmunoGen, Inc. is a clinical-stage biotechnology company that develops targeted cancer therapeutics using its antibody-drug conjugate (ADC) technology. An ADC with the Company’s technology comprises an antibody that binds to a target found on tumor cells conjugated to one of its anti-cancer agents as a payload to kill the tumor cell once the ADC has bound to its target. Its product candidates include Mirvetuximab soravtansine; IMGN779; IMGN632; and Coltuximab ravtansine. Its portfolio is led by Mirvetuximab soravtansine, a first-in-class ADC targeting folate-receptor alpha (Fra), which is in a Phase III registrational trial called FORWARD I. Its FORWARD II trial consists of cohorts assessing Mirvetuximab soravtansine in combination with Avastin (bevacizumab), Keytruda (pembrolizumab) and carboplatin. The Company has developed tubulin-acting maytansinoid payload agents, which include DM1 and DM4, as well as deoxyribonucleic acid (DNA)-alkylating agents called IGNs.

About Ohr Pharmaceuticals

OHR Pharmaceutical, Inc., a pharmaceutical company, focuses on the development of novel therapeutics and delivery technologies for the treatment of ocular disease. Its lead clinical program is topical Squalamine, a small molecule anti-angiogenic drug, which could provide a non-invasive therapy to enhance vision outcomes. The company is evaluating Squalamine, which completed Phase II clinical trials for the treatment of retinal diseases, including wet-AMD, proliferative diabetic retinopathy, and retinal vein occlusion. Its preclinical pipeline of sustained release programs include sustained release formulations of small molecule and protein therapeutics for the treatment of ocular diseases, such as glaucoma, steroid induced glaucoma, ocular allergy, and retinal disease. OHR Pharmaceutical, Inc. is headquartered in New York, New York.

Latest News

Leave a Reply